lung cancer

Views & Analysis

Staying on the cutting edge of oncology advances

Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen antibody could be lung cancer breakthrough

The FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with lung cancer, whose disease has progressed after chemotherapy and are unlike

News

FDA to quickly review Roche's chemo-free lung cancer regimen

Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n

News

Jazz targets US launch of SCLC drug after FDA grants fast re...

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

News

FDA to quickly review Novartis' capmatinib in rare lung canc...

The FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung cancer.

News

Boosted by Celgene's cash, BMS bounces back after mega-merge...

Bristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year results from the previously struggling pharma.

Staying on the cutting edge of oncology advances

Janssen antibody could be lung cancer breakthrough

FDA to quickly review Roche's chemo-free lung cancer regimen

Jazz targets US launch of SCLC drug after FDA grants fast re...

FDA to quickly review Novartis' capmatinib in rare lung canc...

Boosted by Celgene's cash, BMS bounces back after mega-merge...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

lung cancer

Editor's Picks